AMENDMENT NO. 6 TO THEEnbrel® Supply Agreement • February 28th, 2008 • Amgen Inc • Biological products, (no disgnostic substances)
This Amendment No. 6 (“Amendment No. 6”) is made this 27th day of November, 2007 (the “Amendment No. 6 Effective Date”) by and among IMMUNEX CORPORATION, a corporation of the State of Washington, having its principal place of business at One Amgen Center Drive, Thousand Oaks, California, 91320, U.S.A., together with its Affiliates (“Immunex”), WYETH (formerly known as American Home Products Corporation), a corporation of the State of Delaware having its corporate headquarters at Five Giralda Farms, Madison, New Jersey 07940, U.S.A. and acting through its Wyeth Pharmaceuticals Division (“Wyeth”), and BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, (formerly doing business as “Boehringer Ingelheim Pharma KG”) a German corporation having a place of business at Birkendorfer Straße 65, 88397 Biberach an der Riss, Federal Republic of Germany (“BIP”), and amends the Enbrel Supply Agreement effective as of November 5, 1998, by and among Immunex, Wyeth, and BIP, and as amended (the “Agreement”).
ContractAmgen Inc • February 28th, 2008 • Biological products, (no disgnostic substances) • New York
AGREEMENT OF RESIGNATION, APPOINTMENT AND ACCEPTANCE, dated as of February 15, 2008 by and among Amgen Inc., a corporation duly organized and existing under the laws of Delaware and having its principal office at One Amgen Center Drive, Thousand Oaks, California 91320 (the “Company”), The Bank of New York, a New York banking corporation having a corporate trust office at 700 South Flower Street, Suite 500, Los Angeles, California 90017 (“Successor Trustee”) and CITIBANK, N.A., a national banking association duly organized and existing under the laws of the United States of America and having its principal corporate trust office at 388 Greenwich Street, New York, New York 10013 (“Resigning Trustee”).
